(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 April 2010 (29.04.2010)

PCT

(10) International Publication Number
WO 2010/048352 A8

(51) International Patent Classification:
*C12N 15/113* (2010.01) *A61K 31/711* (2006.01)

(21) International Application Number:
PCT/US2009/061570

(22) International Filing Date:
22 October 2009 (22.10.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/196,995 22 October 2008 (22.10.2008) US
61/198,931 11 November 2008 (11.11.2008) US
PCT/IL2009/000179
15 February 2009 (15.02.2009) IL

(71) Applicant *(for all designated States except US)*: **Quark Pharmaceuticals, Inc.** [US/US]; 6501 Dumbarton Circle, Fremont, California 94555 (US).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **FEINSTEIN, Elena** [IL/IL]; 12/29 HaHagana Street, 76214 Rehovot (IL). **ALPERT, Evgenia** [IL/IL]; Apartment 14, 25 Kobobi street, 96757 Jerusalem (IL). **METT, Igor** [IL/IL]; 9/1 Paldi Street, 76248 Rehovot (IL). **BAR-ILAN, Amir** [IL/IL]; 12 Shoshanat Hacarmel Street, 34321 Haifa (IL). **SPIVAK, Igor** [IL/IL]; Rabbi Y. Ha-Nassi Street 8/16, 35425 Haifa (IL). **KALINSKI, Hagar** [IL/IL]; 23 Zalman Shazar Street, 75700 Rishon-le-Zion (IL). **SLAGER, Netanja** [NL/IL]; 176/4 Ben Yehuda Street, 53471 Tel Aviv (IL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,

*[Continued on next page]*

(54) Title: METHODS FOR TREATING EYE DISORDERS

Figure 1B




(57) Abstract: The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at 5 least one siRNA which down regulates expression of a target gene associated with loss of the retinal ganglion cell, thereby inhibiting loss of the retinal ganglion cell in the subject. The methods of the invention also relate to the use of chemically modified siRNA compounds possessing structural motifs which down-regulate the expression of human genes expressed in retinal tissue in the mammalian eye.

WO 2010/048352 A8

NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

**(84) Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published**:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

**(88) Date of publication of the international search report**:
17 June 2010

**(48) Date of publication of this corrected version**:
11 August 2011

**(15) Information about Correction**:
see Notice of 11 August 2011